menu
    • menu

    Company profile for CR Double-Crane Pharmaceuticals Co., Ltd

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-08-11

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemi...
    CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CR Double-Crane Pharmaceuticals Co., LtdChina Flag
    Country
    Country
    China
    Address
    Address
    No.1 Suzhou Road, Zhecheng County, Henan Province
    Telephone
    Telephone
    +86-15738220354
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.dcpc.com/en/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI Korea

    Not Confirmed

    envelop Contact Supplier

    CPhI Korea

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    "50 Years of Innovation: Mikart

    mic"50 Years of Innovation: Mikart's legacy and what's next in CDMO excellence"

    This week, SpeakPharma interviews Michael Kallelis, CEO of Mikart, a leading contract development and manufacturing organization (CDMO) celebrating its 50th anniversary in the pharmaceutical industry. Based in the United States, Mikart has built a reputation for technical expertise, flexible business terms, and specialized capabilities in pharmaceutical development services. In this exclusive interview, Kallelis discusses how Mikart maintains its competitive edge through its Pharmaceutical Development Services team, quality control framework, and commitment to customized business solutions. Kallelis also explores the company's focus on liquid suspensions manufacturing, driven by growing demand from aging populations and pediatric patients, and explains how Mikart balances traditional family business values with modern innovation. HIGHLIGHTS// celebrating its 50th anniversary/ reputation for technical expertise/ how Mikart maintains its competitive edge Mikart is celebrating 50 years in business this year — what are some of the major milestones that have shaped the company's journey? Over our 50-year history, we've celebrated many memorable milestones, but one of the most significant in recent years has been achieving our growth objectives. This success was driven by the strategic expansion of our Pharmaceutical Development Services team, the completion of full aggregate serialization in our packaging department, modernization of our IT systems, enhanced productivity, and our ability to attract both new and returning customers. HIGHLIGHTS// expansion of our Pharmaceutical Development Services team/ completion of full aggregate serialization/ attract both new and returning customers How has Mikart maintained its competitive edge in a constantly evolving pharmaceutical landscape? Our customers consistently tell us that what sets us apart is our technical expertise, high service level, and flexible, customized business terms. At the core of our competitiveness is our focus on Pharmaceutical Development Services (PDS). Mikart's PDS opinion leaders are actively engaged in business development and form early, collaborative relationships with our customers' technical teams. From the outset, our prospects and clients work directly with Mikart's experienced formulation chemists, analytical method developers, and process-oriented engineers to design robust, reproducible, and efficient processes. This hands-on development approach is supported by a comprehensive quality control testing framework — covering raw material testing, in-process checks, on-site microbiological testing, and in-house stability studies. Oversight is provided by our robust Quality Management System, managed by a dedicated Quality Assurance and Regulatory Affairs team. The result is disciplined problem-solving, timely FDA submissions, and a "right-first-time" philosophy that accelerates time-to-market. We operate with a strong sense of urgency and consistently deliver a high level of customer satisfaction. What truly differentiates Mikart is our commitment to customized business terms that eliminate common roadblocks seen with other CDMOs. Our secret sauce is our exceptional service and flexibility in helping our customers bring innovative medicines to patients. HIGHLIGHTS// technical expertise, high service level/ flexible, customized business terms/ comprehensive quality control testing framework/ dedicated Quality Assurance and Regulatory Affairs team/ timely FDA submissions/ accelerates time-to-market What capabilities or services does Mikart offer today that didn't exist 10 or 20 years ago? Mikart was an early leader in serialization, implementing full capabilities well ahead of the industry timeline. This proactive approach has kept our packaging team in high demand. We also upgraded our tablet compression equipment to enhance both speed and reliability. To support growing development needs, we invested in new lab-scale development equipment, unit dose cup filling, sachet packaging, low-humidity suites, and a brand-new suite dedicated to closed-system manufacturing of liquids and suspensions. Most recently, we launched a multi-million dollar expansion of our packaging lines to support higher-speed tablet filling, powder-in-bottle formats, and new liquid fill capabilities. HIGHLIGHTS// early leader in serialization/ upgraded our tablet compression equipment/ multi-million dollar expansion of our packaging lines Why are liquid suspensions becoming such a key focus, and how is Mikart positioned? Formulating suspensions is a complex process that requires specialized expertise and equipment. According to our customers, few mid-market CDMOs do it well — and Mikart is one of them. There is growing industry demand for high-quality suspension manufacturing, driven by the needs of the aging baby boomer population and pediatric patients. For both groups, swallowing tablets or capsules can be difficult, making oral liquid suspensions a more practical alternative. In addition to being easier to administer, suspensions offer pharmacological advantages and can improve dosing compliance. Enhanced flavoring techniques further improve the patient experience — especially for children and infants — by making medicines more palatable. HIGHLIGHTS// growing industry demand for high-quality suspension manufacturing/ suspensions offer pharmacological advantages/ improve dosing compliance How does Mikart balance tradition with innovation to meet modern customer demands? At Mikart, we work hard to preserve the values of a traditional family business, even as we continue to modernize. Our goal is to make every customer feel like they are our top priority. Each customer is supported by a dedicated project manager who serves as their primary point of contact, along with direct access to key team members across departments. This structure ensures our customers are never isolated from our subject matter experts and can get timely, accurate answers to their questions. We're also mindful of the "technology trap" — the tendency to pursue every new innovation at the expense of focus and efficiency. Instead, we rely on market data and customer trends to guide our investments, enabling us to concentrate our resources and capital on technologies that meet real market needs. HIGHLIGHTS// customer is supported by a dedicated project manager/ customers are never isolated from our subject matter experts/ we rely on market data and customer trends to guide our investments/ meet real market needs Looking ahead, what's in store for Mikart in the next 5-10 years? Mikart's strategic plan is now in full motion, and with the momentum we've built, 50 percent growth is within reach. This projection is backed by a strong pipeline of annual FDA filings, a growing customer base, and a robust portfolio of active Pharmaceutical Development Services projects. As we grow, we remain committed to delivering exceptional service and continuously evolving to meet the changing needs of our customers. With renewed political emphasis on domestic manufacturing for the US market, we are ideally positioned to support the rapid, cost-effective development and production of high-quality medicines here at home. As we approach our 50th anniversary in the CDMO industry, we celebrate our legacy and look forward with optimism to the opportunities ahead in the next 5 to 10 years. HIGHLIGHTS// 50 percent growth is within reach/ strong pipeline of annual FDA filings 

    Impressions: 2221

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence

    PharmaCompass
    17 Jul 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaQuality, Reliability, TrustQuality, Reliability, Trust

    Quality, Reliability, Trust
    Quality, Reliability, Trust

    reelQuality, Reliability, Trust

    This PharmaReel highlights Rochem’s capabilities in sourcing and supplying Generic APIs and Excipients, driven by Quality, Reliability, and Trust through fully cGMP-compliant operations. With over 30 years of experience and 16 offices worldwide, Rochem continues to develop partnerships across the US, China, Europe, and South America.

    Impressions: 2606

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired  Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord).  Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 7105

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint

    #PharmaFlow by PHARMACOMPASS
    10 Jul 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Ligand, CR Double-Crane Collaborate to Develop an Oral COVID-19 Therapeutic
    Ligand, CR Double-Crane Collaborate to Develop an Oral COVID-19 Therapeutic

    21 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211021005381/en

    BUSINESSWIRE
    21 Oct 2021
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Acetazolamide

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AGGSpend
    Not Confirmed
    arrow

    02

    Allopurinol

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AGGSpend
    Not Confirmed
    arrow

    03

    Brivudine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AGGSpend
    Not Confirmed
    arrow

    04

    Edaravone

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AGGSpend
    Not Confirmed
    arrow

    05

    Ethamsylate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AGGSpend
    Not Confirmed
    arrow

    06

    Ipratropium Bromide

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AGGSpend
    Not Confirmed
    arrow

    07

    Parecoxib Sodium

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AGGSpend
    Not Confirmed
    arrow

    08

    Pregabalin

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AGGSpend
    Not Confirmed
    arrow

    09

    Tetramethylpyrazine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AGGSpend
    Not Confirmed
    arrow

    10

    Ticagrelor

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AGGSpend
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    LISTED APIs

    read-more
    read-more
    Contact Supplier
      • fda
      • EDQM
      • WHO-GMP
      Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

      Acetazolamide

      Product
      Web Link

      Stock Recap
      #PipelineProspector

      Market
      Place

      CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. wh...
      CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.
      blank

      01

      Acetazolamide

      China
      AGGSpend
      Not Confirmed
      arrow

      Acetazolamide

      China
      arrow
      AGGSpend
      Not Confirmed
      • fda
      • EDQM
      • WHO-GMP
      Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

      CR Double-Crane Pharmaceuticals Co., Ltd

      CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.

      About the Company : CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals F...

      blank

      Product
      Web Link

      Stock Recap
      #Pipeline Prospector

      Market
      Place

      Contact Supplier
        • fda
        • EDQM
        • WHO-GMP
        Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

        Allopurinol

        Product
        Web Link

        Stock Recap
        #PipelineProspector

        Market
        Place

        CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. wh...
        CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.
        blank

        02

        Allopurinol

        China
        AGGSpend
        Not Confirmed
        arrow

        Allopurinol

        China
        arrow
        AGGSpend
        Not Confirmed
        • fda
        • EDQM
        • WHO-GMP
        Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

        CR Double-Crane Pharmaceuticals Co., Ltd

        CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.

        About the Company : CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals F...

        blank

        Product
        Web Link

        Stock Recap
        #Pipeline Prospector

        Market
        Place

        Contact Supplier
          • fda
          • EDQM
          • WHO-GMP
          Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

          ALOGLIPTIN BENZOATE

          Product
          Web Link

          Stock Recap
          #PipelineProspector

          Market
          Place

          CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. wh...
          CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.
          blank

          03

          ALOGLIPTIN BENZOATE

          China
          AGGSpend
          Not Confirmed
          arrow

          ALOGLIPTIN BENZOATE

          China
          arrow
          AGGSpend
          Not Confirmed
          • fda
          • EDQM
          • WHO-GMP
          Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

          CR Double-Crane Pharmaceuticals Co., Ltd

          CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.

          About the Company : CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals F...

          blank

          Product
          Web Link

          Stock Recap
          #Pipeline Prospector

          Market
          Place

          Contact Supplier
            • fda
            • EDQM
            • WHO-GMP
            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

            alpha-Lobeline hydrochloride

            Product
            Web Link

            Stock Recap
            #PipelineProspector

            Market
            Place

            CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. wh...
            CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.
            blank

            04

            alpha-Lobeline hydrochloride

            China
            AGGSpend
            Not Confirmed
            arrow

            alpha-Lobeline hydrochloride

            China
            arrow
            AGGSpend
            Not Confirmed
            • fda
            • EDQM
            • WHO-GMP
            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

            CR Double-Crane Pharmaceuticals Co., Ltd

            CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.

            About the Company : CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals F...

            blank

            Product
            Web Link

            Stock Recap
            #Pipeline Prospector

            Market
            Place

            Contact Supplier
              • fda
              • EDQM
              • WHO-GMP
              Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

              brivudine

              Product
              Web Link

              Stock Recap
              #PipelineProspector

              Market
              Place

              CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. wh...
              CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.
              blank

              05

              brivudine

              China
              AGGSpend
              Not Confirmed
              arrow

              brivudine

              China
              arrow
              AGGSpend
              Not Confirmed
              • fda
              • EDQM
              • WHO-GMP
              Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

              CR Double-Crane Pharmaceuticals Co., Ltd

              CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.

              About the Company : CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals F...

              blank

              Product
              Web Link

              Stock Recap
              #Pipeline Prospector

              Market
              Place

              Contact Supplier
                • fda
                • EDQM
                • WHO-GMP
                Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                Dequalinium Chloride

                Product
                Web Link

                Stock Recap
                #PipelineProspector

                Market
                Place

                CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. wh...
                CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.
                blank

                06

                Dequalinium Chloride

                China
                AGGSpend
                Not Confirmed
                arrow

                Dequalinium Chloride

                China
                arrow
                AGGSpend
                Not Confirmed
                • fda
                • EDQM
                • WHO-GMP
                Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                CR Double-Crane Pharmaceuticals Co., Ltd

                CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.

                About the Company : CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals F...

                blank

                Product
                Web Link

                Stock Recap
                #Pipeline Prospector

                Market
                Place

                Contact Supplier
                  • fda
                  • EDQM
                  • WHO-GMP
                  Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                  edaravone

                  Product
                  Web Link

                  Stock Recap
                  #PipelineProspector

                  Market
                  Place

                  CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. wh...
                  CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.
                  blank

                  07

                  edaravone

                  China
                  AGGSpend
                  Not Confirmed
                  arrow

                  edaravone

                  China
                  arrow
                  AGGSpend
                  Not Confirmed
                  • fda
                  • EDQM
                  • WHO-GMP
                  Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                  CR Double-Crane Pharmaceuticals Co., Ltd

                  CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.

                  About the Company : CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals F...

                  blank

                  Product
                  Web Link

                  Stock Recap
                  #Pipeline Prospector

                  Market
                  Place

                  Contact Supplier
                    • fda
                    • EDQM
                    • WHO-GMP
                    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                    Etamsylate

                    Product
                    Web Link

                    Stock Recap
                    #PipelineProspector

                    Market
                    Place

                    CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. wh...
                    CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.
                    blank

                    08

                    Etamsylate

                    China
                    AGGSpend
                    Not Confirmed
                    arrow

                    Etamsylate

                    China
                    arrow
                    AGGSpend
                    Not Confirmed
                    • fda
                    • EDQM
                    • WHO-GMP
                    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                    CR Double-Crane Pharmaceuticals Co., Ltd

                    CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.

                    About the Company : CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals F...

                    blank

                    Product
                    Web Link

                    Stock Recap
                    #Pipeline Prospector

                    Market
                    Place

                    Contact Supplier
                      • fda
                      • EDQM
                      • WHO-GMP
                      Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                      Etoricoxib

                      Product
                      Web Link

                      Stock Recap
                      #PipelineProspector

                      Market
                      Place

                      CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. wh...
                      CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.
                      blank

                      09

                      Etoricoxib

                      China
                      AGGSpend
                      Not Confirmed
                      arrow

                      Etoricoxib

                      China
                      arrow
                      AGGSpend
                      Not Confirmed
                      • fda
                      • EDQM
                      • WHO-GMP
                      Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                      CR Double-Crane Pharmaceuticals Co., Ltd

                      CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.

                      About the Company : CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals F...

                      blank

                      Product
                      Web Link

                      Stock Recap
                      #Pipeline Prospector

                      Market
                      Place

                      Contact Supplier
                        • fda
                        • EDQM
                        • WHO-GMP
                        Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                        IPRATROPIUM BROMIDE

                        Product
                        Web Link

                        Stock Recap
                        #PipelineProspector

                        Market
                        Place

                        CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. wh...
                        CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.
                        blank

                        10

                        IPRATROPIUM BROMIDE

                        China
                        AGGSpend
                        Not Confirmed
                        arrow

                        IPRATROPIUM BROMIDE

                        China
                        arrow
                        AGGSpend
                        Not Confirmed
                        • fda
                        • EDQM
                        • WHO-GMP
                        Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                        CR Double-Crane Pharmaceuticals Co., Ltd

                        CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals Factory, the company was listed on Shanghai Stock Exchange in 1997 with Stock Code as 600062. In 2010, it was merged into China Resources (Group) Co, Ltd. which is one of the Global 500 companies and became the main manufacturer of chemical medicines under the Group. In 2012, the company was officially renamed from Beijing Double-Crane Pharmaceuticals Co., Ltd. to CR Double-Crane Pharmaceuticals Co., Ltd.

                        About the Company : CR Double-Crane Pharmaceuticals Co., Ltd (hereinafter referred to as CR Double-Crane) is a pharmaceuticals company with 75 years of brilliant history. Formerly known as Beijing Pharmaceuticals F...

                        blank

                        Product
                        Web Link

                        Stock Recap
                        #Pipeline Prospector

                        Market
                        Place

                        Only 10 entries up to this point, click to access all click full view read-more
                        click full view
                        Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

                        FDA Orange Book

                        read-more
                        read-more

                        01

                        Brand Name : FLUOXETINE HYDROCHLO...

                        China
                        AGGSpend
                        Not Confirmed
                        arrow

                        Brand Name : FLUOXETINE HYDROCHLO...

                        China
                        AGGSpend
                        Not Confirmed
                        arrow
                        • fda
                        • EDQM
                        • WHO-GMP
                        Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                        RLD : No

                        TE Code :

                        FLUOXETINE HYDROCHLORIDE

                        CR Double-Crane Pharmaceuticals Co., Ltd

                        Dosage Form : CAPSULE; ORAL

                        Proprietary Name : FLUOXETINE HYDROCHLORIDE

                        Dosage Strength : EQ 10MG BASE

                        Approval Date : 2002-02-01

                        Application Number : 76165

                        RX/OTC/DISCN : DISCN

                        RLD : No

                        TE Code :

                        blank

                        Product
                        Web Link

                        Stock Recap
                        #PipelineProspector

                        Market
                        Place

                        02

                        Brand Name : FLUOXETINE HYDROCHLO...

                        China
                        AGGSpend
                        Not Confirmed
                        arrow

                        Brand Name : FLUOXETINE HYDROCHLO...

                        China
                        AGGSpend
                        Not Confirmed
                        arrow
                        • fda
                        • EDQM
                        • WHO-GMP
                        Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                        RLD : No

                        TE Code :

                        FLUOXETINE HYDROCHLORIDE

                        CR Double-Crane Pharmaceuticals Co., Ltd

                        Dosage Form : CAPSULE; ORAL

                        Proprietary Name : FLUOXETINE HYDROCHLORIDE

                        Dosage Strength : EQ 20MG BASE

                        Approval Date : 2002-02-01

                        Application Number : 76165

                        RX/OTC/DISCN : DISCN

                        RLD : No

                        TE Code :

                        blank

                        Product
                        Web Link

                        Stock Recap
                        #PipelineProspector

                        Market
                        Place

                        03

                        Brand Name : MELOXICAM

                        China
                        AGGSpend
                        Not Confirmed
                        arrow

                        Brand Name : MELOXICAM

                        China
                        AGGSpend
                        Not Confirmed
                        arrow
                        • fda
                        • EDQM
                        • WHO-GMP
                        Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                        RLD : No

                        TE Code :

                        MELOXICAM

                        CR Double-Crane Pharmaceuticals Co., Ltd

                        Dosage Form : TABLET; ORAL

                        Proprietary Name : MELOXICAM

                        Dosage Strength : 7.5MG

                        Approval Date : 2006-12-14

                        Application Number : 78039

                        RX/OTC/DISCN : DISCN

                        RLD : No

                        TE Code :

                        blank

                        Product
                        Web Link

                        Stock Recap
                        #PipelineProspector

                        Market
                        Place

                        04

                        Brand Name : MELOXICAM

                        China
                        AGGSpend
                        Not Confirmed
                        arrow

                        Brand Name : MELOXICAM

                        China
                        AGGSpend
                        Not Confirmed
                        arrow
                        • fda
                        • EDQM
                        • WHO-GMP
                        Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                        RLD : No

                        TE Code :

                        MELOXICAM

                        CR Double-Crane Pharmaceuticals Co., Ltd

                        Dosage Form : TABLET; ORAL

                        Proprietary Name : MELOXICAM

                        Dosage Strength : 15MG

                        Approval Date : 2006-12-14

                        Application Number : 78039

                        RX/OTC/DISCN : DISCN

                        RLD : No

                        TE Code :

                        blank

                        Product
                        Web Link

                        Stock Recap
                        #PipelineProspector

                        Market
                        Place

                        Inspections and registrations

                        Upload your audits for free, ask us

                        ABOUT THIS PAGE

                        Contact CR Double-Crane Pharmaceuticals Co., Ltd and get a quotation

                        CR Double-Crane Pharmaceuticals Co., Ltd is a supplier offers 17 products (APIs, Excipients or Intermediates).

                        Find a price of Acetazolamide bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Allopurinol bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Alogliptin Benzoate bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Brivudine bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Dequalinium Chloride bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Edaravone bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Ethamsylate bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Etoricoxib bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Ipratropium Bromide bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Lobeline Hydrochloride bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Metoclopramide bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Parecoxib Sodium bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Pregabalin bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Tetramethylpyrazine bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Ticagrelor bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Tofacitinib Citrate bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Find a price of Triamterene bulk offered by CR Double-Crane Pharmaceuticals Co., Ltd

                        Ask Us for Pharmaceutical Supplier and Partner
                        Ask Us, Find A Supplier / Partner
                        No Commissions, No Strings Attached, Get Connected for FREE

                        What are you looking for?

                        How can we help you?

                        The request can't be empty

                        Please read our Privacy Policy carefully

                        You must agree to the privacy policy

                        The name can't be empty
                        The company can't be empty.
                        The email can't be empty Please enter a valid email.
                        The mobile can't be empty

                        Market Place

                        Market Place

                        PharmaCompass

                        Home

                        Market Place

                        Menu

                        Post Enquiry

                        Post Enquiry

                        Market Place

                        Market Place

                        Search